Home » Stocks » Cidara Therapeutics

Cidara Therapeutics, Inc. (CDTX)

Stock Price: $3.90 USD 0.11 (2.90%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 160.35M
Revenue (ttm) 23.45M
Net Income (ttm) -39.07M
Shares Out 41.12M
EPS (ttm) -1.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.90
Previous Close $3.79
Change ($) 0.11
Change (%) 2.90%
Day's Open 3.80
Day's Range 3.79 - 3.96
Day's Volume 69,407
52-Week Range 1.22 - 4.45

More Stats

Market Cap 160.35M
Enterprise Value 97.57M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 41.12M
Float 31.28M
EPS (basic) -1.2
EPS (diluted) -1.33
FCF / Share -0.70
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.21M
Short Ratio 5.68
Short % of Float 6.86%
Beta 1.88
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.84
PB Ratio 2.90
Revenue 23.45M
Operating Income -39.88M
Net Income -39.07M
Free Cash Flow -26.58M
Net Cash 62.78M
Net Cash / Share 1.53
Gross Margin -108.71%
Operating Margin -170.10%
Profit Margin -180.30%
FCF Margin -113.35%
ROA -33.59%
ROE -85.71%
ROIC 537.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(71.03% upside)
Current: $3.90
Target: 6.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit20.92------
Operating Income-41.72-63.29-55.72-48.44-32.31-11.62-1.08
Net Income-41.09-59.02-55.73-48.17-32.19-11.89-1.34
Shares Outstanding29.0925.1417.5014.499.920.820.32
Earnings Per Share-1.41-2.76-3.18-3.32-3.25-14.51-4.15
Operating Cash Flow-28.53-56.71-49.91-39.77-25.96-7.71-1.05
Capital Expenditures-0.04-0.18-0.31-0.40-1.17-0.99-
Free Cash Flow-28.57-56.88-50.22-40.17-27.13-8.70-1.05
Cash & Equivalents60.2774.5675.3110510822.800.19
Total Debt11.739.939.879.79--1.48
Net Cash / Debt48.5464.6365.4494.8310822.80-1.30
Book Value37.8459.1459.7488.18104-11.45-1.40
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cidara Therapeutics, Inc.
Country United States
Employees 68
CEO Jeffrey L. Stein

Stock Information

Ticker Symbol CDTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CDTX
IPO Date April 15, 2015


Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases in the United States. Its lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. The company, through its Cloudbreak platform, focuses on the treatment of infectious diseases that include viral and bacterial infections. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in June 2014. Cidara Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.